Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Provided By GlobeNewswire
Last update: Aug 22, 2024
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
